Organogenesis Holdings Profit Margin

Organogenesis Holdings (ORGO) currently reports a profit margin of -16.92% as of June 2026. That compares with -2.56% in the prior-year period — down 561.9% year over year. That is below the Healthcare sector average of 14.34%. Use the charts on this page to explore Organogenesis Holdings's profit margin history and peer comparisons.

Organogenesis Holdings's profit margin decreased from -2.56% to -16.92% — a 561.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Organogenesis Holdings's profit margin of -16.92% is lower than the Healthcare sector average of 14.34%. That is roughly 217.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Organogenesis Holdings's current -16.92% should be judged against Healthcare norms (sector average: 14.34%) and against ORGO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -16.92%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Organogenesis Holdings, and consider following ORGO for alerts when major investors trade the stock.